contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bioretec-publishes-a-company-description-for-the-contemplated-listing-of-its-shares-on-nasdaq-first-north-growth-market-finland

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Some buyer unfamiliar with the matter is on the buy side of the stock market, offering an opportunity to sell shares to them at an inflated price. Yes, the price will drop, at the latest when the share issue project has been completed and the harsh reality dawns on the majority of owners. A reverse split is coming at some point, though; 100 shares will become 1 share or something similar. In listed companies, there are always “Penos from next door” as owners, who really don’t understand much about the matter. They just stare at the fact that the share price has dropped -98% and buy because of that; the share looks cheap based on this. They hope for a quick small rise, and if it happens, they sell again. One could, of course, also speculate that someone is consciously trying to maintain a high share price during the share issue. This way, exercising subscription rights looks appealing to existing owners, and more people might participate in the issue. Currently, there’s a buy order for 30,000 shares at €0.0488 each on the buy side. That’s only €1,440 in money. A small sum when this issue aims to raise €15 million from investors. One could almost consider it a marketing expense. The company is made to look more valuable by maintaining a high buy side, and if the shares have to be bought, it’s not a big loss. The goal for the large owners here is to make the share issue succeed by almost any means necessary. On the other hand, the previous shares of existing owners have already lost almost all their value. It’s not worth the trouble of selling shares if the trading commission is greater than the value of the shares. In these situations, the stock market price can be almost anything for a few weeks during the issue.

The market isn’t always efficient. I don’t think it’s anything more than inertia.

I’m a bit puzzled by Bioretec’s share price… Before the warrants were spun off on Fri 27.3., the share price was about 14c and the company’s market value was 4.31m. Today, according to Nordnet, the company has 1,508,616,508 shares, which, at a share price of 5 cents, results in a market value of 75.43m.  The company is expected to receive a maximum of 14.77m more money through the offering, in which case the theoretical market value should be 4.31m + 14.77m = 19.08m. Could someone wiser tell me why the company’s market value (and the theoretical share price after the offering) has increased by 295%… or have I perhaps forgotten/missed something???

Here are Antti’s thoughts on, among other things, the rights issue, in the form of a company report.  Bioretec announced the terms of its rights issue on Friday. The company aims to raise a maximum of 14.8 MEUR. The minimum target of 5 MEUR for the issue is guaranteed by the main owner. The share will trade without subscription rights on Monday, so we have factored the issue into our model. Our revenue and earnings forecasts remain unchanged, but we are raising our required rate of return in line with the persistently high risk level. We reiterate our Add recommendation, as despite significant commercialization headwinds over the past year, we believe the company is doing the right things and still has the potential to succeed. We revise our target price to 0.018 euros (previously 0.32 €).                   Inderes              Bioretec: Anti maaliin huhtikuun aikana - Inderes    Bioretec toteuttaa merkintäoikeusannin huhtikuun loppuun mennessä.

Inside Information: Bioretec Oy’s Board of Directors Decided on a Rights Offering of a Maximum of Approximately EUR 14.8 Million and Publishes the Terms of the Rights Offering                   Inderes              Sisäpiiritieto: Bioretec Oy:n hallitus päätti enintään noin 14,8 miljoonan...    Bioretec Oy Sisäpiiritieto 27.3.2026 klo 12:50Sisäpiiritieto: Bioretec Oy:n hallitus päätti enintään noin 14,8 miljoonan euron merkintäetuoikeusannista ja julkaisee merkintäetuoikeusannin ehdotEI...

Inderes              Bioretec: Finanssivalvonta on myöntänyt Stephen Industries Inc Oy:lle ja...    Bioretec Oy Yhtiötiedote 26.3.2026 klo 17:50Finanssivalvonta on myöntänyt Stephen Industries Inc Oy:lle ja Kustaa Poutiaiselle pysyvän luvan poiketa velvollisuudesta tehdä pakollinen julkinen...                             Now that the exemption has been granted, the offering will probably start soon.

Thank you @Vino_Pino ! I completely missed this. I’ve even been checking LinkedIn from time to time to see what Paavola’s situation is after the sudden departure from NGH. And today was so strange; while I was writing my previous message, I had already double-checked several times that the CFO on BRETEC’s website was a completely different (female) person. I swear on my honor that the CFO on BRETEC’s website changed to Paavola while I was drafting my previous post. I was really worried about NGH when Paavola left their position with 5 minutes’ notice and the CEO gave downright icy cold “thanks” for absolutely nothing. Now, my feeling regarding this red flag is starting to be quite the opposite. (Perhaps) more on this in NGH’s own thread. o tempora - o mores

Bioretec

Bioretec Ltd Company release 24 September 2021 at 4.30 p.m. EESTBioretec Ltd ("Bioretec" or the "Company") announced on 20 September 2021 that it had submitted a listing application with Nasdaq...

<div class="abstract">Bioretec Ltd&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Company release&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24 September 2021 at 4.30 p.m. EEST</div>Bioretec Ltd ("Bioretec" or the "Company") announced on 20 September 2021 that it had submitted a listing application with Nasdaq Helsinki Ltd ("Nasdaq Helsinki") for listing of the Company's shares (the&nbsp;"Shares") on Nasdaq First North Growth Market Finland maintained by Nasdaq Helsinki (the&nbsp;"Listing").For the purposes of the Listing, Bioretec has prepared a Finnish-language company description in accordance with the Nasdaq First North Growth Market Rulebook (the "Company Description"). Nasdaq Helsinki has today, on 24 September 2021, reviewed the Company Description. The Company Description will be published on the website of the Company at www.bioretec.com/listautuminen on or about 24 September 2021.Subject to the listing application of the Company being approved, trading in the Shares of the Company on Nasdaq First North Growth Market Finland is expected to commence on or about 28 September 2021. Nordic Certified Adviser AB will act as Bioretec's certified adviser in accordance with the Nasdaq First North Growth Market Rulebook.Further enquiriesTimo Lehtonen, CEO, tel. +358 50&nbsp;433 8493Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132Certified Adviser:Nordic Certified Adviser AB, tel. +46 70 551 67 29Information about BioretecBioretec's mission is to promote healing after trauma or orthopedic surgery, building on a unique understanding of bioresorbable medical implants that act as scaffolds for tissue growth and eliminate the need for removal surgery of the implants. Bioretec's bioresorbable polymer implants are used worldwide and the Company intends to launch a new series of innovative implants based on a unique bioresorbable metallic alloy, RemeOs[TM]. The RemeOs[TM] product line is designed to meet the unmet medical need of demanding load-bearing fixations, and to facilitate a seamless transition for surgeons from conventional titanium implants. Better healing - Better life.